(SLGL) Sol-Gel Technologies Ltd. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SLGL) Sol-Gel Technologies Ltd. Complete Analysis Pack
Download Your Competitive Advantage
This Sol-Gel Technologies Ltd. BCG Matrix helps you quickly see how the company’s products or business units may fall into Stars, Cash Cows, Question Marks, and Dogs for strategy and portfolio planning. The content on this page is a real preview of the actual analysis, so you can review the format and scope before buying. Purchase the full version to get the complete ready-to-use report instantly.
Stars
Twyneo, acne vulgaris, once-daily
Twyneo, Sol-Gel Technologies Ltd.’s lead acne asset, finished Phase III and is approved for once-daily topical use. Its non-antibiotic profile helps it stand out in a U.S. acne market that affects about 50 million people each year. With active commercialization support and a clear clinical edge, it fits the Star bucket.
Epsolay, papulopustular rosacea, once-daily
Epsolay is a once-daily, Phase III rosacea therapy for papulopustular disease, which supports easier use and stronger brand pull in dermatology. Sol-Gel Technologies reported 2024 net revenue of $3.1 million, while the U.S. rosacea market is estimated at over $1 billion, giving Epsolay clear growth runway. That mix of clinical validation and market size fits a Star.
Perrigo partnership, commercialization platform
Perrigo gives Sol-Gel a scaled route to market for topical dermatology, cutting launch risk versus a small in-house rollout. Perrigo had about $4.4 billion in 2024 net sales, so its reach and execution should speed uptake and widen access. In BCG terms, this partnership acts like a Star enabler because it supports growth, market access, and faster commercialization.
Microencapsulation technology, core delivery platform
Sol-Gel Technologies Ltd.’s microencapsulation platform is the core of its skin-applied drug design, and it has already supported 2 approved brands, Epsolay and Twyneo. Because the same delivery know-how can be reused across products and indications, the platform can keep turning one asset into multiple launchable products, which is Star-like behavior in a focused niche.
- Reusable platform lowers development risk
- 2 approved products validate the engine
- Supports repeat launches across dermatology
Branded topical dermatology franchise, Israel to U.S. launch
Sol-Gel Technologies Ltd. is centered on branded skin-applied medicines, not broad pharma diversification. Its 2 FDA-approved products, EPSOLAY and TWYNEO, give the franchise a real U.S. launch platform, but the brand still needs promotion and shelf space to scale.
That fits a Star in transition: high-growth potential, early-stage commercialization, and ongoing cash burn pressure until repeat prescribing builds. The Israel base helps supply, but the U.S. market decides the value.
- 2 FDA-approved branded dermatology products.
- U.S. launch is real, but still scaling.
- Needs promotion, access, and repeat use.
- Star in transition, not a mature Cash Cow.
Sol-Gel’s Dermatology Stars: Twyneo and Epsolay Have Room to Run
Sol-Gel Technologies Ltd.’s Stars are Twyneo and Epsolay: both FDA-approved, once-daily dermatology products with clear U.S. growth room. Twyneo targets a ~50 million-person acne market, while rosacea demand is still large and underused. Perrigo’s $4.4 billion 2024 sales base supports scale, so these assets fit a Star profile.
| Asset | Signal | Data |
|---|---|---|
| Twyneo | Acne Star | Phase III done; approved |
| Epsolay | Rosacea Star | Phase III done; approved |
| Perrigo | Scale support | $4.4B 2024 net sales |
What is included in the product
Detailed Word Document
Sol-Gel’s BCG Matrix maps its dermatology portfolio to pinpoint Stars, Cash Cows, Question Marks, and Dogs for invest, hold, or divest.
Editable Excel File
One-page BCG Matrix for Sol-Gel Technologies Ltd. to quickly spot growth, cash, and risk units
Reference Sources
Provides a traceable source trail for Sol-Gel Technologies Ltd., strengthening credibility and speeding investor and strategy decisions.
Cash Cows
Generic topical dermatology, mature segment
Generic topical dermatology is a mature, low-growth niche with steady prescription demand, so it fits the Cash Cow profile if Sol-Gel Technologies Ltd. can defend share with low spend. Sol-Gel reported $16.4 million in cash and cash equivalents at June 30, 2025, giving it room to support this kind of efficient, recurring business. The play is simple: small marketing, stable volume, dependable cash flow.
Royalty and milestone income, partnered products
Sol-Gel Technologies Ltd.’s partnered products can generate royalty and milestone income without the Company carrying the full sales force, inventory, and launch spend. Once development and launch costs are mostly behind the Company, this becomes a high-margin, cash-generating BCG Cash Cow. The model fits mature assets: low capital need, recurring receipts, and upside when partner sales rise.
Perrigo revenue base, lower internal spend
Perrigo’s large consumer-health revenue base helps Sol-Gel’s partnership model behave like a Cash Cow: once a product is launched, Sol-Gel can rely more on partner promotion and less on its own sales force and placement spend. Perrigo reported about $4.3 billion in net sales in FY2024, showing the scale that can support steady, lower-cost commercial execution. That setup helps protect margins and convert mature products into recurring cash flow.
Validated microencapsulation IP, reusable asset
Sol-Gel Technologies Ltd.’s validated microencapsulation IP fits a Cash Cow profile because the first proof of the delivery platform does the heavy lift, and each new skin-care or dermatology use case should cost less to develop. That lowers the marginal R&D burden and makes the IP base more efficient over time. Mature platform IP can keep producing returns with limited reinvestment.
- Proven platform lowers repeat development cost
- Reusable IP improves capital efficiency
- Mature IP can sustain steady cash flow
Approved dermatology brands, maintenance phase
Approved dermatology brands in Sol-Gel Technologies Ltd.'s maintenance phase fit BCG's Cash Cow profile: launch spend drops, promotion gets lighter, and cash conversion usually improves as growth slows. That shift matters because mature topical products need far less support than launch-stage brands, so each sales dollar can throw off more cash. In Sol-Gel Technologies Ltd.'s case, the value comes from steady prescription demand, not heavy new-brand spending.
Lower launch spend
Slower growth, steadier cash
Maintenance phase = Cash Cow
Sol-Gel’s Cash Cows Drive Steady, Efficient Cash Flow
Sol-Gel Technologies Ltd.’s Cash Cows are its mature dermatology assets and partner-led products: low launch spend, lighter promotion, and recurring receipts. At June 30, 2025, Sol-Gel Technologies Ltd. held $16.4 million in cash and cash equivalents, while Perrigo’s FY2024 net sales were about $4.3 billion, supporting efficient commercialization and steadier cash conversion.
| Driver | Data |
|---|---|
| Sol-Gel cash | $16.4M |
| Cash date | Jun. 30, 2025 |
| Perrigo sales | $4.3B FY2024 |
Preview the Actual Deliverable
Sol-Gel Technologies Ltd. Reference Sources
The Sol-Gel Technologies Ltd. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No mockups, no watermarks, and no placeholder content—just the full, ready-to-use file. Download it instantly and use it for analysis, presentations, or strategic planning. What you see here is what you get.
Dogs
Commodity topical copies, weak pricing power
Sol-Gel Technologies Ltd.'s commodity topical copies can fit the Dogs box if scale stays thin: low share, weak pricing power, and margins that get squeezed by fixed costs. In 2025/2026, small generic launches in crowded dermatology markets often deliver little cash while inventory and working capital still consume capital. That setup can trap value instead of creating it.
Early exploratory formulations, no clear edge
Sol-Gel Technologies Ltd.’s early exploratory formulations fit Dogs because they have no clear edge and little proof of scale. In 2025, projects like this can burn R&D cash while still failing to win meaningful share, which is why they are hard to defend in a BCG Matrix. Without a sharp clinical or commercial lead, they stay small, costly, and low-return.
Unpartnered low-visibility work, limited reach
Sol-Gel Technologies Ltd. has shown that unpartnered assets with low visibility can become Dogs fast: they lack a commercial partner, so traction is slow and sales reach stays narrow. That matters when management time is already tied to the 2 lead brands, which makes weak-growth projects even harder to fund and scale. In BCG terms, these assets fit the Dog profile because low visibility and low growth usually mean low return on effort.
Minor line extensions, crowded topical niche
Sol-Gel Technologies Ltd’s minor line extensions sit in a crowded topical skin market where small tweaks rarely create scale. When larger rivals can copy fast, spend more, and reach more doctors and pharmacies, low-share products stay weak and behave like Dogs. That dynamic is sharper when the category is already fragmented and promotion-heavy.
- Small extension, weak moat
- Big peers can outspend
- Low share limits profit
- Dog profile if scale stays thin
Legacy R&D spend, no disclosed approval path
Sol-Gel Technologies Ltd.’s legacy R&D spend fits Dogs in BCG terms because it consumes cash without a clear approval path or near-term market launch. That kind of spending can crowd out capital for the lead acne and rosacea assets, where the commercial case is stronger. In BCG, low growth plus weak share usually signals a cash trap, not a growth engine.
- Cash use, no visible path to approval
- Diverts funds from acne and rosacea leads
- Best fit: Dogs
Sol-Gel’s Dogs: Low Share, Weak Growth, and a Cash Drag
Sol-Gel Technologies Ltd.’s Dogs are the low-share, low-growth assets that tie up cash and management time. In 2025/2026, they look weakest next to the 2 lead brands because they have thin scale, weak pricing power, and little proof of durable demand.
| Dog signal | Sol-Gel Technologies Ltd. |
|---|---|
| Share | Low |
| Growth | Weak |
| Capital use | Cash drag |
Question Marks
SGT-210, Phase I, palmoplantar keratoderma
SGT-210 is in Phase I for palmoplantar keratoderma, so its current market share is effectively zero. With no approved revenue and only early clinical data, Sol-Gel Technologies Ltd. faces high execution risk here. If future trials show strong skin-clearance and tolerability, rare-disease dermatology could become attractive, but today this is a classic Question Mark.
Erlotinib topical program, psoriasis and other uses
Sol-Gel Technologies Ltd.'s erlotinib topical program is still pre-commercial, so its revenue contribution is $0 and its upside depends on trial readouts and uptake. Erlotinib’s repurposing for psoriasis and other skin uses could create value, but there is no established market position yet. That mix of possible growth and no proven sales makes it a clear Question Mark.
Tapinarof investigation, psoriasis-related development
Tapinarof is a dermatology option worth watching, but Sol-Gel Technologies Ltd. still has no marketed psoriasis share, so this stays a Question Mark. Psoriasis affects about 125 million people worldwide, which makes the niche large enough to matter if the program advances. Until clinical and regulatory progress is proven, the asset has upside but no current cash flow.
Roflumilast investigation, inflammatory skin disease
Roflumilast sits in a fast-growing topical inflammation market, with U.S. psoriasis affecting about 7.5 million adults and atopic dermatitis about 16.5 million adults. Sol-Gel Technologies Ltd. still has no proven commercial scale in this niche, so the asset’s revenue upside is still untested. By BCG logic, that makes it a Question Mark: high market potential, but weak share and unclear return.
- Large unmet need, but no proven Sol-Gel sales base
- Growth is real; execution risk is still high
- Question Mark until share and cash returns improve
New topical pipeline candidates, low share today
Any new Sol-Gel Technologies Ltd. candidate starts with low share and high uncertainty, because there is no launch sales base yet. In BCG terms, these are Question Marks until real prescription and revenue data prove demand.
Dermatology can scale fast if the product is clearly better on efficacy, safety, or ease of use. Until Sol-Gel posts launch data, uptake, payer access, and repeat-use trends, the pipeline stays a Question Mark.
Low share, high risk
Needs launch proof
Differentiation drives scale
Sol-Gel’s High-Upside, High-Risk Pipeline Faces a Proof Test
Sol-Gel Technologies Ltd.’s Question Marks have big addressable markets but no proven share yet, so their upside is real and their cash conversion is still untested. With SGT-210 in Phase I and other assets still pre-commercial, each program remains high-risk until launch data and prescriptions prove demand.
| Asset | Status | Market signal |
|---|---|---|
| SGT-210 | Phase I | 0 share |
| Roflumilast | Pre-scale | US psoriasis 7.5M |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.